ChemoCentryx Hit With Investor Suit Over Drug Trial Claims
ChemoCentryx Inc. has been hit with a proposed investor class action in California federal court accusing the biopharmaceutical company of overstating the efficacy of its newly developed treatment for an autoimmune...To view the full article, register now.
Already a subscriber? Click here to view full article